Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunther Hartmann

Showing results (1-10 of 199) with videos related to

Pageof 20
Sort By:
Nucleic Acid Therapeutics|February 21, 2012
A message from the Oligonucleotide Therapeutics SocietyGunther Hartmann
Idrugs : the Investigational Drugs Journal|July 6, 2006
TIDES 2006--IBC conference. Oligonucleotide and peptide technology and product development. 1-3 May 2006, Carlsbad, CA, USAGunther Hartmann
The Journal of Clinical Investigation|March 24, 2009
Gene silencing below the immune radarGunther Hartmann
Molecular Therapy. Nucleic Acids|December 19, 2023
Cooperative activation of human TLR9 and consequences for the clinical development of antisense and CpG oligodeoxynucleotidesGunther Hartmann
Current Opinion in Molecular Therapeutics|June 16, 2004
Technology evaluation: BAY-50-4798, BayerGunther Hartmann
Immunity|July 16, 2020
Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic AcidsEva Bartok, Gunther Hartmann
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 24, 2019
Targeted Nanoparticle Delivery of Bifunctional RIG-I Agonists to Pancreatic CancerThomas Zillinger, Gunther Hartmann
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2010
The chase for the RIG-I ligand--recent advancesMartin Schlee, Gunther Hartmann
Nature Reviews. Immunology|July 26, 2016
Discriminating self from non-self in nucleic acid sensingMartin Schlee, Gunther Hartmann
Current Opinion in Immunology|November 5, 2022
Innate sensing of mRNA vaccinesChristine Wuebben, Eva Bartok, Gunther Hartmann
Pageof 20

Showing results (1-10 of 199) with videos related to

Sort By:
Pageof 20
Nucleic Acid Therapeutics|February 21, 2012
A message from the Oligonucleotide Therapeutics SocietyGunther Hartmann
Idrugs : the Investigational Drugs Journal|July 6, 2006
TIDES 2006--IBC conference. Oligonucleotide and peptide technology and product development. 1-3 May 2006, Carlsbad, CA, USAGunther Hartmann
The Journal of Clinical Investigation|March 24, 2009
Gene silencing below the immune radarGunther Hartmann
Molecular Therapy. Nucleic Acids|December 19, 2023
Cooperative activation of human TLR9 and consequences for the clinical development of antisense and CpG oligodeoxynucleotidesGunther Hartmann
Current Opinion in Molecular Therapeutics|June 16, 2004
Technology evaluation: BAY-50-4798, BayerGunther Hartmann
Immunity|July 16, 2020
Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic AcidsEva Bartok, Gunther Hartmann
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 24, 2019
Targeted Nanoparticle Delivery of Bifunctional RIG-I Agonists to Pancreatic CancerThomas Zillinger, Gunther Hartmann
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2010
The chase for the RIG-I ligand--recent advancesMartin Schlee, Gunther Hartmann
Nature Reviews. Immunology|July 26, 2016
Discriminating self from non-self in nucleic acid sensingMartin Schlee, Gunther Hartmann
Current Opinion in Immunology|November 5, 2022
Innate sensing of mRNA vaccinesChristine Wuebben, Eva Bartok, Gunther Hartmann
Pageof 20